Rising Arthritis Cases Fueling Market Growth For Rheumatoid Arthritis Drugs: Pivotal Factor Influencing Rheumatoid Arthritis Drugs Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Rheumatoid Arthritis Drugs Market Size Growth Forecast: What to Expect by 2025?
In recent years, there has been a slight decline in the rheumatoid arthritis drugs market size. It is projected to rise from "$60.3 billion in 2024 to $60.1 billion in 2025, with a compound annual growth rate (CAGR) of -0.3%. Factors contributing to growth in the historic period include the growing prevalence of the disease, the advancement of healthcare infrastructure, heightened awareness and educational endeavors, governmental support and initiatives, as well as strategic collaborations.

How Will the Rheumatoid Arthritis Drugs Market Size Evolve and Grow by 2029?
Expectations are high for the rheumatoid arthritis drugs market size as it's anticipated to undergo continuous growth in the upcoming years. This market is predicted to reach a value of $65.34 billion by 2029, marking a compound annual growth rate (CAGR) of 2.1%. Factors contributing to the projected growth during the forecast period include the rise in personalized medicine trends, the growth of emerging markets, pipeline development, focus on combination therapies, and increased healthcare expenditure. Key trends in the forecast period include the dominance of biological therapies, impact of biosimilars, advancements in personalized medicine, growth of oral therapies, with a heavy emphasis on early diagnosis and intervention.

View the full report here:
https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report

What Drivers Are Propelling the Growth of Rheumatoid Arthritis Drugs Market Forward?
The escalating incidence of arthritis is slated to boost the expansion of the rheumatoid arthritis drugs market. Rheumatoid arthritis is characterized as an autoimmune and inflammatory condition wherein the immune system deliberately damages healthy cells in the body, which results in inflammation or painful swelling in the affected body parts. Both pharmaceuticals specifically for rheumatoid arthritis and self-management methodologies are widely accessible for effective RA treatment. The use of these drugs diminishes discomfort, increases joint flexibility and obstructs disease progression. For example, the National Center for Health Statistics, a government agency based in the US, reported in February 2024 that the age-adjusted prevalence of diagnosed arthritis among adults in 2022 was 18.9%, with females (21.5%) being more frequently afflicted than males (16.1%). This prevalence grew significantly with escalating age, rising from 3.6% in adults aged between 18 and 34 to 53.9% in those aged 75 and above. Hence, the increasing instances of arthritis are anticipated to fuel the growth of the rheumatoid arthritis drug market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10120&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Rheumatoid Arthritis Drugs Market?
The advent of product innovations is a notable trend surging in popularity within the rheumatoid arthritis drug market. Corporations operating in this medical sector are launching novel products in an effort to maintain their market position. To illustrate, in August 2022, R-Pharm, a privately owned high-tech pharmaceutical company from Russia, introduced Olokizumab - a humanized monoclonal antibody. This antibody specifically targets the cytokine interleukin-6, a messenger molecule contributing to the progression of joint destruction in rheumatoid arthritis and induces inflammatory responses akin to TNF (tumor necrosis factor). This action effectively reduces the disease's activity in a significant number of rheumatoid arthritis patients.

What Are the Key Segments in the Rheumatoid Arthritis Drugs Market?
The rheumatoid arthritis drugs market covered in this report is segmented -

1) By Drug Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Disease-Modifying Antirheumatic Drugs (DMARDs), Biologic Response Modifiers (BRMs), Other Drug Types
2) By Route Of Administration: Oral, Parenteral, Topical, Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:
1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Diclofenac, Indomethacin
2) By Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone
3) By Disease-Modifying Antirheumatic Drugs: Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide
4) By Biologic Response Modifiers: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, B-cell Inhibitors
5) By Other Drug Types: Janus Kinase Inhibitors, Other Novel Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10120&type=smp

Who Are the Key Players Shaping the Rheumatoid Arthritis Drugs Market's Competitive Landscape?
Major companies operating in the rheumatoid arthritis drugs market include Pfizer Inc., Abbvie Inc., Amgen Inc., Novartis AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, F-Hoffmann La Roche AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Merck & Co Inc., Johnson & Johnson Inc., Bayer AG, Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A, Biogen Inc., Regeneron Pharmaceuticals Inc., Galapagos NV, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, UCB S.A., Astellas Pharma Inc., Corbus Pharmaceuticals Holdings Inc., Roche Holding AG, Daiichi Sankyo Company Limited, Mallinckrodt Pharmaceuticals, Gilead Sciences Inc.

What Geographic Markets Are Powering Growth in the Rheumatoid Arthritis Drugs Market?
North America was the largest region in the rheumatoid arthritis drugs market in 2024.North America is expected to be the fastest-growing region in the global rheumatoid arthritis market report during the forecast period. The regions covered in the rheumatoid arthritis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10120

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.